Inflarx NV at JPMorgan Healthcare Conference Transcript
Okay. We'll go ahead and get started. So welcome to the Thursday session of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.
Our next presenting company is InflaRx, and presenting on behalf of the company is CEO, Niels Riedemann. Niels?
Yes. Thanks so much, Anupam, for inviting us here. Good morning, everyone. I would also like to welcome those listening in on the webcast.
Before I start, I have to advise you that I will be making forward-looking statements and you know that there's disclaimers that come with that.
Now InflaRx is about C5a-inhibiting technology. We've dedicated about 20 years of research towards this goal, and we are the leading company in the anti-C5a space. We have drugs, 2 drugs, in development that are capable of completely and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |